Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer: What is the Optimal Initiation Time for the Maximum Benefit?

Author： Needleman Sarah J.   Tobias Jeffrey S.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.68, Iss.1, 2008-01, pp. : 1-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

By Ligibel Jennifer A.   Winer Eric P.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 2, 2003-04 ,pp. : 215-221

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Everolimus in the treatment of hormone receptor-positive breast cancer

By Chavez-MacGregor Mariana   Gonzalez-Angulo Ana Maria  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1835-1843

Informa Healthcare

Access to resources Recommend Favorite

Aromatase inhibitors: the new first-line therapy in breast cancer?

By  

Inpharma, Vol. 1, Iss. 1265, 2000-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Which anthracycline dose optimal in node-positive breast cancer?

By  

Inpharma, Vol. 1, Iss. 1279, 2001-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite